1月6日A股早盘延续开年强势，量能再度刷新近期纪录，市场交易活跃度攀升至高位。 证券ETF(159841)，对应场外联接基金（A：008590，C：008591）。 【热点事件】 A股放量逼空！成交额连续6日破2万亿 截至2026年1月6日 14:31，证券ETF(159841)盘中换手10.27%，成交10.91亿元，市场交投活跃。跟踪的中证全指证券公司指数 (399975)强势上涨4.13%，成分股华林证券(002945)上涨9.99%，华安证券(600909)上涨9.99%，长江证券(000783)上涨6.63%，国 泰海通(601211)，东方财富(300059)等个股跟涨。 【产品亮点】 证券板块具备较强β属性，主营业务表现与资本市场表现息息相关，因此被喻为"牛市旗手"。历史市场反弹期间，证券板块显著 跑赢大盘，深市规模流动性同类持续领先的证券ETF(159841)助力把握机遇。 【相关产品】 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 沪深两市成交额实现连续第6个交易日突破2万亿，早盘阶段较前一交易日同期放量超1500亿，预计全天成交金额超2.7万亿，有 望创出近期成交 ...

12月19日，A股三大指数午后高位震荡。截至收盘，沪指涨0.36%，深成指涨0.66%，创业板指涨 0.49%。沪深两市成交额1.73万亿，较上一个交易日放量704亿。市场逾4400股上涨。港股市场，恒生指 数收涨0.75%，恒生科技指数涨1.12%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 2 | 3890.45c | 14.08 | 0.36% | | 399001 | 深证成指 | mr. Vin | 13140.21 c | 86.24 | 0.66% | | 399006 | 创业板指 | | Nom 3122.24c | 15.17 | 049% | 资金流向，主力资金全天净流入通用设备、汽车、商贸零售等板块，净流出半导体、航天航空、电子等 板块。盘面上，大消费爆发，零售、免税店方向领涨；海南自贸区、核聚变、稀土永磁、两岸融合、智 能驾驶概念股活跃。算力硬件产业链调整，CPO、存储区方向跌幅靠前。 美日数据及政策动向主导市场情绪 12月18日，在政府结束停摆后 ...

根据世界卫生组织预测，全球每年约有10亿例季节性流感病例，包括300万至500万例重症病例。在此 背景下，抗流感药物市场空间广阔。据头豹研究院预测，2024—2028年中国抗流感用药市场规模将以 20.2%的年复合增长率持续增长，到2028年有望达到269亿元。 （资料参考：21世纪经济报道《抗流 感药需求激增：市场"厮杀"升级，谁能抢占C位？》,2025.11.3) 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新 药元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结 果。这背后蕴藏着什么投资机遇？ （资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上 市，另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加 入市场竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗 效、安全性方面获得了认可。 （资料参考：央广 ...

百亿市场待重构，替代空间广阔 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新药 元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结果。 这背后蕴藏着什么投资机遇？（资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上市， 另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加入市场 竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗效、安全性 方面获得了认可。（资料参考：央广网《全国整体进入流感流行季 多款国产流感创新药密集上市》， 2025.11.21；36氪《围剿"流感神药"奥司他韦，药厂卷起"一次治疗"新战场》，2025.11.14） 突破进口药局限，实现多重优化 国产新药与进口流感药玛巴洛沙韦作用机制相同，都是通过抑制流感病毒的CAP帽子结构依赖性内切 酶，从而阻断病毒复制。值得关注的是，这批国产新药并非简 ...

【导读】上周五股票 ETF资金 净流出 44 亿元， 11 月净流入超 700 亿元 中国基金报记者 天心 上周五（ 11 月 28 日）， A 股市场低开高走，三大指数集体收涨，沪深两市成交量缩至 1.59 万亿元。 伴随市场反弹，部分股票 ETF 选择"落袋为安"。上周五全市场股票 ETF （含跨境 ETF ）资金净流出 44 亿元。 11 月份，股票 ETF 仍 大幅 " 吸金 " 超 700 亿元。其中，恒生科技相关 ETF 获得资金青睐，合计资金净流入接近 200 亿元。 半导体、卫星、稀有金属 ETF 领涨 Wind 数据显示，截至 11 月 28 日，全市场 1268 只股票 ETF 总规模达 4.55 万亿元。 当日股票 ETF 成交额合计 1421.21 亿元，与前一交易日 1777.47 亿元相比缩量超 350 亿元。其中，易方达基金旗下 A500ETF 当日成 交 56.37 亿元，位居首位。 此外， A500ETF 易方达、中证 A500ETF （国泰基金）成交额在 40 亿元以上。创新药 ETF （广发）、 A500ETF 基金华泰柏瑞、中韩 半导体 ETF （华泰柏瑞）、 A500 ...

Market Overview - A-shares experienced a slight rebound today, with the Shanghai Composite Index rising by 0.05% to 3836.77 points and the Shenzhen Component Index increasing by 0.37% to 12585.08 points. The total trading volume decreased slightly to 1.7 trillion yuan, indicating a market that has released previous gains but still faces some adjustment pressure [1] - The gaming sector showed strength today, with the gaming ETF (516010) increasing by 3.22%. Despite a recent pullback, the industry's fundamentals remain strong, and the cost reduction through AI continues, suggesting a favorable entry point for investors [1] Hong Kong Market - The Hong Kong stock market rebounded significantly, with the Hang Seng Index rising by 1.97% to 25716.50 points and the Hang Seng Tech Index increasing by 2.78% to 5545.56 points. Despite previous concerns over high valuations in the AI sector, the current low valuations present a buying opportunity for investors [2] Gold Market - In the gold market, the U.S. non-farm payrolls exceeded expectations, but the unemployment rate increased, leading to fluctuating interest rate expectations. Geopolitical tensions, particularly between Russia and Ukraine, and ongoing tensions between China and Japan, have increased demand for gold as a safe haven [2] - The outlook for gold remains supported by the potential for a Federal Reserve rate cut cycle, increasing macroeconomic uncertainty, and a global trend towards de-dollarization, suggesting a strategic opportunity for investors to accumulate gold ETFs (518800) [2] Innovative Pharmaceuticals - The newly established commercial insurance innovative drug catalog provides a potential funding pool of approximately 20 billion yuan for innovative drugs. The innovative drug sector is showing positive growth, with revenues reaching 48.56 billion yuan, a year-on-year increase of 21.41%, and a significant reduction in net profit losses [3] - The increasing approval of domestic innovative drugs and their international market expansion indicate a promising future for the innovative drug industry, with investment opportunities available through innovative drug ETFs (517110) and the Guotai Science and Technology Innovative Drug ETF (589720) [3]

Market Overview - The market is experiencing weakness with the Shanghai Composite Index opening lower and declining further, while the Shenzhen Component and ChiNext indices saw a slight reduction in their losses towards the end of the trading session [1] - There is rapid rotation of market hotspots, with the lithium battery industry chain experiencing a collective surge, the Fujian sector maintaining strength, and AI application concepts gaining momentum [1] ETF Performance - Rare metals ETFs showed significant gains, with the following performances: - 159608.SZ Rare Metals ETF increased by 3.68% - 562800.SH Rare Metals ETF rose by 3.66% - 561800.SH Rare Metals ETF Fund up by 3.22% [2] Industry Insights - Analysts suggest that the limited reserves of strategic minor metals, along with high extraction difficulties and insufficient supply elasticity, are leading to intensified supply-demand conflicts due to rapid growth in downstream demand from sectors like new energy, semiconductors, and military industry [3] - The ongoing scarcity of resources, upgrading demand structure, and policy adjustments are expected to drive rare metal prices upward, benefiting companies with resource reserves, technological barriers, and compliant export channels [3] Declining Sectors - The innovative pharmaceutical sector and gold-related ETFs have seen declines, with the following notable drops: - 589720.SH Innovative Drug ETF down by 2.7% - 159562.SZ Gold Stock ETF decreased by 2.57% [4][5] Biotechnology Developments - The biotechnology sector in China is witnessing positive developments, with multiple innovative drug companies having 35 studies selected for oral presentations at the ESMO 2025 conference, setting a new record [5] - Significant collaborations are emerging, such as the partnership between Innovent Biologics and Takeda, valued at up to $11.4 billion, reflecting global market recognition of the value of Chinese innovative drugs [5]

Group 1 - The core viewpoint indicates a decline in innovative drug concept stocks, with notable drops in companies such as Kanglong Chemical, Kelun Pharmaceutical, and Xinlitai, among others [1] - The innovative drug-related ETFs have also experienced a decline, with an overall drop exceeding 2% [1] - Despite the downturn, there have been positive developments in China's biotechnology sector, including 35 research presentations at the ESMO 2025 conference and significant collaborations like the $11.4 billion partnership between Innovent Biologics and Takeda, highlighting global recognition of Chinese innovative drug value [2]

Market Overview - The A-share market exhibited a range-bound fluctuation with reduced volatility, indicating a stabilization in market sentiment. The major indices, including the Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index, experienced declines of 0.18%, 1.40%, and 3.01% respectively [1] - The trading volume in the Shanghai and Shenzhen markets fell below 2 trillion yuan on several days, reflecting a significant decrease in market activity and a growing sense of caution among investors [1] - The average decline of all ETFs was 0.62%, with commodity ETFs showing a notable increase of 2.95%, while cross-border ETFs also performed well with an average increase of 1.55% [1] ETF Performance - The innovative drug sector is showing signs of recovery, with nine out of the top ten performing ETFs related to innovative drugs, some exceeding a 7% increase. The overall revenue of the innovative drug sub-sector grew by 23.34%, and the CXO sector's net profit increased by 55.90% year-on-year, significantly outperforming the industry average [2][3] - The communication and AI-related ETFs continued to decline as the market adjusts to the valuations of previously high-performing sectors. However, this short-term adjustment may provide better long-term investment opportunities [4] Fund Trends - Despite market fluctuations, thematic ETFs remain the main attraction for capital, with a net inflow of 145.37 billion yuan during the period. Stock ETFs saw a net inflow of 46.20 billion yuan, indicating a preference for equity investments [5] - Gold and brokerage ETFs attracted significant capital inflows, with the gold ETF receiving over 2.5 billion yuan, highlighting a strong demand for safe-haven assets [7] ETF Issuance Market - Two new ETFs are set to launch next week, including the Huaxia CSI Photovoltaic Industry ETF, which tracks the performance of companies involved in the photovoltaic industry chain, reflecting China's strong position in the global photovoltaic market [9] - The Southern Hang Seng Technology ETF aims to track the Hang Seng Technology Index, which covers various sectors of the technology industry, indicating potential growth in the Hong Kong stock market [10]

Group 1: ETF Market Overview - The three major indices experienced fluctuations and declines, with the Shanghai Composite Index down by 0.07%, the Shenzhen Component Index down by 0.36%, and the ChiNext Index down by 0.39. Notably, several pharmaceutical ETFs, particularly the innovative drug ETFs, saw gains, with the Fortune Innovative Drug ETF rising by 1.89% and the Guotai Innovative Drug ETF increasing by 1.85% [1] - As of November 11, 2023, a total of 317 ETFs have been launched this year, with a combined scale of 541.17 billion yuan. This marks a significant increase compared to 163 and 156 ETFs launched in 2024 and 2023, respectively, indicating a rapid expansion in the ETF market [2] - The number of newly issued funds this year has reached 1,371, the highest in nearly three years. However, the average fundraising scale for new funds is only 78.2 million yuan, reflecting a shift in the public fund issuance market towards a more diversified and institutionalized approach [3] Group 2: Regulatory Insights - The Vice Chairman of the China Securities Regulatory Commission, Li Ming, emphasized the importance of preventing significant market fluctuations and maintaining stability. He highlighted the strong fundamentals of the Chinese economy and the need for long-term investment strategies to enhance market stability [4] Group 3: ETF Performance - The overall performance of ETFs varied, with cross-border ETFs showing the best average return of 1.18%, while thematic stock index ETFs had the worst average return of -0.58% [10] - The top-performing ETFs today included the Sci-Tech Innovative Drug ETF from Huatai, which rose by 1.99%, followed by the Fortune Innovative Drug ETF and the Guotai Innovative Drug ETF, both increasing by 1.89% [12][13] - In terms of trading volume, the top three stock ETFs were the CSI A500 ETF, with a trading volume of 4.965 billion yuan, followed by the A500 ETF Fund and the A500 ETF from E Fund, with trading volumes of 4.944 billion yuan and 4.552 billion yuan, respectively [15]